[Ip-health] Fwd: TAG Welcomes HHS Lawsuit Against Gilead; Urges Dramatic Scale-Up of Low-Cost PrEP

Suraj Madoori suraj.madoori at treatmentactiongroup.org
Mon Nov 11 10:17:24 PST 2019


TAG Welcomes HHS Lawsuit Against Gilead; Urges Dramatic Scale-Up of
Low-Cost PrEP


November 11, 2019 – Treatment Action Group (TAG) welcomes the U.S.
Department of Health and Human Services (HHS) pursuit of a lawsuit
against Gilead Sciences, Inc., the manufacturer of Truvada and
Descovy, the only two FDA-approved pills for pre-exposure prophlyaxis
(PrEP) to prevent HIV. The suit is the result of months of pressure by
activists who have rightly asserted that tenofovir-based PrEP research
was underwritten by U.S. taxpayers, many of whom remain shut-out from
accessing  PrEP due to financial barriers arising directly from the
corporate price gouging.

For years, the drugmaker Gilead has profited off of taxpayer funded
research by charging excessive prices for PrEP. Gilead’s high pricing
has limited the scope of initiatives to end the HIV
epidemic—particularly among low-income communities and communities of
color. While TAG and allies call for a dramatic overhaul of the
current U.S. patent system, in the meantime, TAG urges the U.S.
government to capitalize on this opportunity to hold Gilead
accountable for its profiteering and invest any financial compensation
in strategies to scale up PrEP to achieve the vision of ending the HIV
epidemic in the U.S.

"Ultimately, this must be about immediate and dramatically scaled up
access to PrEP for the most marginalized communities in America. For
months, advocates have called on the US government to vigorously
defend taxpayer investments in tenofovir-based PrEP research; this
lawsuit sets the stage for Gilead to be held accountable for billions
in unearned revenue,” said Jeremiah Johnson, Director of the HIV
Project at TAG. He adds, “Gilead's price gouging has created enormous
barriers to access for those most in need of this essential HIV
prevention technology; any damages awarded to the government must be
fully invested in community-led PrEP navigation programs and other
initiatives to increase awareness and utilization."

###

About TAG: Treatment Action Group (TAG) is an independent, activist
and community-based research and policy think tank fighting for better
treatment, prevention, a vaccine, and a cure for HIV, tuberculosis,
and hepatitis C virus.

--
Suraj Madoori
U.S. and Global Health Policy Director
Treatment Action Group
mobile: +1.917.530.5996
www.treatmentactiongroup.org


Treatment Action Group
90 Broad St, Suite 2503
New York, NY 10004 USA
tel: +1.212.253.7922
fax: +1.212.253.7923
www.treatmentactiongroup.org



More information about the Ip-health mailing list